Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Stock Information for Palisade Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Palisade Bio Inc.

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.